Table 2.
Name | Origins | Methods | Results | Pathways |
| ||||
Astragalus | Radix astragali | Human study (DN patients) | Decreasing BUN, Scr, and proteinuria and improving CCr and serum albumin level | [63] |
Type 2 diabetic animal study (KK-Ay mice) | Increasing Smad7 expression, inhibiting TGFβR-1, Smad3, and its phosphorylation expression, and decreasing TGF-β1 mRNA level | Rebalancing TGFβ/Smads signaling [64] | ||
Cellular study (kidney fibroblast) | Upregulating c-met expression | c-met pathway [65] | ||
| ||||
BBR | Coptis chinensis, Hydrastis Canadensis, Berberis aristata, Berberis aquifolium, and Arcangelisia flava | Type 2 diabetic animal study (HFD + STZ induced rats) | Suppressing histological and ultrastructural changes in kidney, improving glucose and lipid metabolism disorder, increasing cAMP, downregulating GRK2 and GRK3, and upregulating GRK6 | Modulating the expression of GRKs in G protein-AC-cAMP signaling pathway [66] |
| ||||
Curcumin | Curcuma longa L.(CLL) | Type 2 diabetic animal study (db/db mice) | Decreasing albuminuria and attenuating glomerular sclerosis | Inhibiting phosphorylation of STAT3 and degradation of IκB [67] |
Cellular study (mesangial cells) | Reducing AGE-induced oxidative stress and restoring AGE-induced mesangial cell apoptosis; Loganin inhibits FN and IL-6 expression | Reducing AGEs-induced ROS [68] | ||
| ||||
DMDD | Tuberous roots of A. carambola L. | Type 2 diabetic animal study (KK-Ay mice) | Decreasing hyperglycemia, renal AGE formation, RAGE, Scr, Ccr, and NF-κB, TGF-β1 and enhancing reduced SOD activities | Decreasing AGEs and TGF-β1 levels [69] |
| ||||
DP | Dragon's blood | Cellular study (human mesangial cells) | Preventing renal fibrosis | Inhibiting SGK1 and FN expression [70] |
| ||||
EGB | Ginkgo biloba leaves | Human study (DN patients) | Decreasing urinary mALB, α1-MG, IgG, TF, RBP, and NAG | Through decreasing sICAM-1 and sVCAM-1 [71, 72] |
Cellular study (mesangial cells) | Suppressing MC hypertrophy and ECM accumulation | Through TGF-β1 and Smads pathway [73] | ||
| ||||
FA | Seeds and leaves of plants | Type 1 diabetic animal study (OLETF rats) | Decreasing blood glucose and urinary ACR, mesangial matrix expansion, and glomerular basement thickness | Through reducing oxidative stress and inflammation [74, 75] |
| ||||
Flos A. manihot | Type 1 diabetic animal study (STZ induced rats) | Preventing renal damage and podocyte apoptosis | [76] | |
| ||||
Genipin | Gardenia jasminoides |
Type 1 diabetic animal study (STZ induced mice) Cellular study (mouse podocyte) |
Ameliorating body weight loss and urine albumin leakage, attenuating GBM thickness, suppressing upregulation of UCP2, and restoring podocin and WT1 expression | Through suppressing upregulation of mitochondrial UCP2 [77] |
| ||||
HCT | Houttuynia Cordata Thunb. | Type 1 diabetic animal study (STZ induced rats) | Reducing UAER, Ccr, TGF-β1, and collagen I and increasing BMP-7 | Decreasing TGF-β1 and increasing BMP-7 [78] |
| ||||
Icariin | Herba epimedii | Type 1 diabetic animal study (STZ induced rats) | Relieving renal damage | Inhibiting TGF-β1 and Col IV expression [79] |
| ||||
LAB | Salvia miltiorrhiza | Type 1 diabetic animal study (STZ induced rats) | Renal MDA↓, microalbuminuria↓, mesangial expansion↓, and glomerular hypertrophy↓ | TGF-β1 pathway [80] |
Cellular study (mesangial cells) | TGF-β1 and fibronectin secretion↓ and PKC and ROS↓ | PKC and ROS pathway [80] | ||
Cellular study (VSMCs) | Inhibiting VSMCs proliferation and migration | Nrf2-ARE-NQO1 [81] | ||
| ||||
LBP | Fruit of goji berry | Type 1 diabetic animal study (STZ induced rats) | Increasing antioxidant enzymes and increasing scavenging oxygen radicals | Via decreased ERK 1/2 activation through PKC [82] |
| ||||
LGP | Averrhoa carambola L. (Oxalidaceae) root | Type 1 diabetic animal study (STZ induced mice) | Decreasing hyperglycemia, NF-κB, caspase-3, caspase-8, caspase-9, and Bax expression; alleviating glomerular hypertrophy and ECM accumulation | [83] |
| ||||
Ligustrazine | Chuangxiong | Human study (DN patients) | Reducing BUN, Scr, 24 h urine protein, urine mAlb, and UAER | [84] |
| ||||
MC | Moutan cortex | Type 2 diabetic animal study (HFD + STZ induced rats) | Increasing SOD, GSH-PX, and CAT, reducing MDA; decreasing blood glucose, Scr, and urine protein and downregulating TGF-β2; decreasing IL-6 and MCP-1, TGF-β1, ICAM-1, and RAGE | Through attenuating oxidative stress and ameliorating inflammation [85–87] |
Cellular studies (HBZY-1 mesangial cell, rat mesangial cells) | Downregulating FN and collagen IV expression | |||
| ||||
Morroniside | Corni fructus | Type 1 diabetic animal study (STZ induced rats) | Increasing decreased serum ALB, reducing elevated BUN, and slowing down Ccr decrease | Through inhibiting hyperglycemia and oxidative stress [88] |
| ||||
PNS | Radixnotoginseng | Type 1 diabetic animal study (STZ induced rats) | Decreasing FBG, Ccr, UAlb, and renal index | Through inhibiting VEGF and TGF-β1 and enhancing BMP-7 and Smad7 [89, 90] |
| ||||
Puerarin | Pueraria candollei | Type 1 diabetic animal study (STZ induced rats) | Decreasing collagen IV; attenuating kidney hypertrophy, mesangial expansion, and proteinuria | Downregulating MMP-9 and eNOS expression [91–93] |
| ||||
Rhein | Rhubarb | Type 2 diabetic animal study (db/db mice) | Decreasing UAE and ECM levels, decreasing TGF-β1 and fibronectin deposition, and decreasing hyperlipidemia | Through decreasing lipid levels [94] |
Cellular study (rat renal PETCs) | Inhibiting cell hypertrophy | [95] | ||
| ||||
R. rosea | Rhodiola rosea | Type 2 diabetic animal study (HFD + STZ induced rats) | Reducing FBG, TC, TG, Ccr, and 24 h urinary albumin | Through decreasing TGF-β1 expression [96] |
| ||||
RLM | Rosa laevigata Michx. | Type 1 diabetic animal study (STZ induced rats) | Increasing SOD activity and total antioxidant capacity, decreasing MDA and ROS levels, and inhibiting NF-κB p65 and MCP-1 expression | Through regulating oxidative stress and inflammation [97] |
| ||||
Sequoyitol | Aristolochia arcuata, Amentotaxus yunnanensis, and Crossostephium chinense | Type 2 diabetic animal study (HFD + STZ induced rats) | Decreasing FBG, BUN, and Scr levels, increasing insulin and T-AOC levels in rats, and decreasing P22phox, P47phox, NF-κB, and TGF-β1 expression in vivo and in vitro | Through glucose-lowering effects, antioxidant activity, and regulation of TGF-β1 expression [98] |
| ||||
SF | Angelica sinensis, Lignsticum chuangxiong, Cimicifuga heracleifolia, and other plants | Human study (DN patients) | Lowering UAER level and improving renal function | Through decreasing (ET) and inhibiting the combination of ET with its receptor [99] |
| ||||
Skimmin | Hydrangea paniculata | Type 1 diabetic animal study (STZ induced rats) | Decreasing Scr and blood glucose level, alleviating glomerular segmental sclerosis and tubular vacuolar degeneration, and downregulating TGF-β1 and TGF-β1 receptor I expression | Through inhibiting TGF-β1 pathway [100] |
| ||||
SM | Salvia miltiorrhiza | Type 1 diabetic animal study (STZ induced rats) | Decreasing TGF-β1, CTGF, PAI-1, FN ED-1, collagen IV, and RAGE overexpression and protecting tubular function and structure | Through inhibiting TGF-β1 pathway, oxidative stress, and inflammation [101–103] |
| ||||
TGP | Paeonia lactiflora Pall. | Type 1 diabetic animal study (STZ induced rats) | Elevating antioxidant enzyme and decreasing p-p38 MAPK and NF-κB Decreasing Scr, BUN, and 24 h UP and improving renal histopathology |
Through inhibiting oxidative stress [104] |
Type 2 diabetic animal study (HFD + STZ induced rats) | Through inhibiting Wnt/beta-catenin signaling pathway [105] | |||
| ||||
TMP | Ligusticum chuanxiong | Type 1 diabetic animal study (STZ induced rats) | Improving renal function | Through downregulating VEGF expression [106] |
| ||||
Triptolide | Diterpene purified from TwHF | Type 2 diabetic animal study (db/db mice) | Decreasing albuminuria, alleviating glomerular hypertrophy and podocyte injury, and attenuating inflammation and oxidative stress in kidney | Through inhibiting inflammation and dyslipidemia [107] |
TwHF | Human study (DN patients) | Preventing podocyte injury | Downregulating TGF-β1, OPN, and CTGF [108] | |
| ||||
VOMBP | Magnolia biondii Pamp. | Type 1 diabetic animal study (STZ induced rats) | Decreasing 24 UmAlb, sP-selectin in serum, and P-selectin in renal tissue | Inhibiting P-selectin [109] |